Press release - Grant of CEP by EDQM
FERMENTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fermenta Biotech has received the Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Healthcare (EDQM) for its spray-dried Vitamin D3 product, VITADEE™ 100 SD (Cholecalciferol Concentrate, 100,000 IU/g), manufactured at its Kullu, Himachal Pradesh facility. With this approval, Fermenta becomes one of only two companies globally to hold a CEP for this specific variant of Vitamin D3. The company, already one of the world's leading Vitamin D3 manufacturers serving over 400 customers across 60 countries, says this accreditation strengthens its regulatory credentials and allows it to move further up the value chain. The announcement comes as Fermenta enters its 75th year of operations.
This is a positive development — the EDQM CEP clears a key regulatory hurdle for selling VITADEE™ 100 SD in European pharmaceutical markets, potentially opening up new export revenue and reinforcing Fermenta's competitive position as a top-tier global Vitamin D3 supplier. The stock may see a positive reaction, though financial impact will depend on how quickly European customers are converted.